Sothema: Strong Growth and a 22% Increase in Net Income by 2025
Sothema: A Prominent Player in Morocco’s Expanding Pharmaceutical Market
In Morocco’s burgeoning pharmaceutical market, Sothema Group has recorded remarkable performance growth in 2025. Its net profit surged by 22%, bolstered by dynamic activity in both private and public sectors and the success of its new product offerings.
The consolidated revenue reached 3.22 billion dirhams, reflecting a 15% increase compared to 2024 and a 14% rise on a like-for-like basis. This growth has been primarily driven by therapeutic areas including oncology, cardiology/diabetology, and autoimmune diseases, all of which act as key engines of the group’s commercial development.
Innovation and New Launches
The year 2025 was notable for 14 new product launches, including 7 locally manufactured products, thereby strengthening Sothema’s portfolio. Among these were a multiple sclerosis treatment based on glatiramer acetate and a biosimilar in oncology targeting breast, lung, and colorectal cancers. The group has also expanded its offerings in cardiology, ophthalmology, gastroenterology, and mental health, solidifying its position in the Moroccan market.
From a regulatory perspective, 20 applications were submitted in 2025, resulting in 18 marketing authorizations and registration certificates obtained, notably in oncology and rheumatology, as well as for dietary supplements.
Strategy and Investments
Sothema has strengthened its external growth strategy through the acquisition of Soludia, which specializes in dialysis solutions, and by signing an agreement with Lilly concerning the brand rights for CIALIS® in the Moroccan market.
Investments for the fiscal year amounted to 85 million dirhams, excluding the acquisition of Soludia, and were primarily dedicated to enhancing industrial capacity.
Financial Performance and Outlook
The consolidated EBITDA increased by 27% to 763 million dirhams, while the operating margin was established at 23.7%, up by 2.4 percentage points.
For 2026, Sothema anticipates continuing its growth trajectory with 25 molecules in development and 30 product launches expected in Morocco, while adapting its industrial capabilities and exploring new opportunities for external growth.
The Board of Directors will propose to the upcoming Ordinary General Assembly the distribution of a gross dividend of 33 dirhams per share, up from 28 dirhams in 2024, totaling 252 million dirhams.
This translation captures the essence and intent of the original French article while ensuring it reads naturally in English, providing a comprehensive overview of Sothema’s recent advancements and future plans in the pharmaceutical landscape.
